Article
Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 May 2011
Amankwah Ernest K, Kelemen Linda E, Wang Qinggang, Song Honglin, Chenevix-Trench Georgia, Beesley Jonathan, Webb Penelope M, Pearce Celeste L, Wu Anna H, Pike Malcolm C, Stram Daniel O, Chang-Claude Jenny, Wang-Gohrke Shan, Ness Roberta B, Goode Ellen L, Cunningham Julie M, Fridley Brooke L, Vierkant Robert A, Tworoger Shelley S, Whittemore Alice S, McGuire Valerie, Sieh Weiva, Gayther Simon A, Gentry-Maharaj Aleksandra, Menon Usha, Ramus Susan J, Rossing Mary Anne, Doherty Jennifer A, Goodman Marc T, Carney Michael E, Lurie Galina, Wilkens Lynne R, Kjær Susanne Krüger, Høgdall Estrid, Cramer Daniel W, Terry Kathryn L, Garcia-Closas Montserrat, Yang Hannah, Lissowska Jolanta, Anton-Culver Hoda, Ziogas Argyrios, Schildkraut Joellen M, Berchuck Andrew, Pharoah Paul D P
Abstract excerpt
BACKGROUND: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI=1.0-1.4, P(trend) = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, P(trend) = 0.003). METHODS: We sought to replicate this association in 12 other studies comprising 4,482 cases...
Read the complete abstract on PubMed